Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset

Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used...

Descripción completa

Detalles Bibliográficos
Autores principales: Pobiruchin, Monika, Bochum, Sylvia, Martens, Uwe M., Kieser, Meinhard, Schramm, Wendelin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802671/
https://www.ncbi.nlm.nih.gov/pubmed/27054173
http://dx.doi.org/10.1016/j.dib.2016.03.039
_version_ 1782422769365942272
author Pobiruchin, Monika
Bochum, Sylvia
Martens, Uwe M.
Kieser, Meinhard
Schramm, Wendelin
author_facet Pobiruchin, Monika
Bochum, Sylvia
Martens, Uwe M.
Kieser, Meinhard
Schramm, Wendelin
author_sort Pobiruchin, Monika
collection PubMed
description Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used to balance the cohorts. Afterwards, documented information about disease events (recurrence of cancer, metastases, remission of local/regional recurrences, remission of metastases and death) found in the dataset was leveraged to calculate the annual transition probabilities for every cohort.
format Online
Article
Text
id pubmed-4802671
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48026712016-04-06 Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset Pobiruchin, Monika Bochum, Sylvia Martens, Uwe M. Kieser, Meinhard Schramm, Wendelin Data Brief Data Article Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used to balance the cohorts. Afterwards, documented information about disease events (recurrence of cancer, metastases, remission of local/regional recurrences, remission of metastases and death) found in the dataset was leveraged to calculate the annual transition probabilities for every cohort. Elsevier 2016-03-12 /pmc/articles/PMC4802671/ /pubmed/27054173 http://dx.doi.org/10.1016/j.dib.2016.03.039 Text en © 2016 Published by Elsevier Inc. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Data Article
Pobiruchin, Monika
Bochum, Sylvia
Martens, Uwe M.
Kieser, Meinhard
Schramm, Wendelin
Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
title Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
title_full Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
title_fullStr Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
title_full_unstemmed Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
title_short Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
title_sort transition probabilities of her2-positive and her2-negative breast cancer patients treated with trastuzumab obtained from a clinical cancer registry dataset
topic Data Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802671/
https://www.ncbi.nlm.nih.gov/pubmed/27054173
http://dx.doi.org/10.1016/j.dib.2016.03.039
work_keys_str_mv AT pobiruchinmonika transitionprobabilitiesofher2positiveandher2negativebreastcancerpatientstreatedwithtrastuzumabobtainedfromaclinicalcancerregistrydataset
AT bochumsylvia transitionprobabilitiesofher2positiveandher2negativebreastcancerpatientstreatedwithtrastuzumabobtainedfromaclinicalcancerregistrydataset
AT martensuwem transitionprobabilitiesofher2positiveandher2negativebreastcancerpatientstreatedwithtrastuzumabobtainedfromaclinicalcancerregistrydataset
AT kiesermeinhard transitionprobabilitiesofher2positiveandher2negativebreastcancerpatientstreatedwithtrastuzumabobtainedfromaclinicalcancerregistrydataset
AT schrammwendelin transitionprobabilitiesofher2positiveandher2negativebreastcancerpatientstreatedwithtrastuzumabobtainedfromaclinicalcancerregistrydataset

Ejemplares similares